Addition/Correction Cite This: J. Med. Chem. XXXX, XXX, XXX−XXX
pubs.acs.org/jmc
Correction to Identification of 5‑(2,3-Dihydro‑1H‑indol-5yl)‑7H‑pyrrolo[2,3‑d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model
Downloaded via 5.62.159.166 on March 8, 2019 at 06:39:59 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles.
Yueshan Li, Yu Xiong, Guo Zhang, Liting Zhang, Wei Yang, Jiao Yang, Luyi Huang, Zeen Qiao, Zhuang Miao, Guifeng Lin, Qiu Sun, Ting Niu, Lijuan Chen, Dawen Niu, Linli Li,* and Shengyong Yang* J. Med. Chem. 2018, 61 (24), 11398−11414. DOI: 10.1021/acs.jmedchem.8b01652 Page 11404. In section 3.8 Preliminary Assessment for the Pharmacokinetic Properties of 22b, “The area under the concentration−time curve (AUC0‑∞) is 14 855.21 mg/L h” should be replaced with “The area under the concentration− time curve (AUC0−∞) is 14 855.21 μg/L h”. “The maximum plasma concentration (Cmax) is 2307 mg/L within about 2 h.” should be replaced with “The maximum plasma concentration (Cmax) is 2307 μg/L within about 2 h.” Page 11406. In Table 7, “Cmax (mg/L)” should be replaced with “Cmax (μg/L)”. “AUC0−∞ (mg/L h)” should be replaced with “Cmax (μg/L h)”.
© XXXX American Chemical Society
A
DOI: 10.1021/acs.jmedchem.9b00368 J. Med. Chem. XXXX, XXX, XXX−XXX
